Abstract
Respiratory syncytial virus (RSV) is one of the most common lower respiratory disease in infants and young children worldwide. Despite its long history, a safe and effective cure for RSV remains elusive. Nonetheless, further understanding of RSV pathogenesis and risk factors have led to advances in prophylaxis and management. The leading risk factor for RSV is premature birth, primarily because fewer protective antibodies are transmitted from the mother to the infant. For full-term born infants, susceptibility to RSV increases as maternal IgG titers decline to a nadir at 2 to 3 months of age. Because of the unique pathophysiologic mechanisms involved in this infection, it is likely that future treatment strategies will focus on modulating the host immune response to the virus, rather than virucidal or virustatic molecules.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
